Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	2.65B
Revenue (ttm)	363.33M
Net Income (ttm)	-707.42M
Shares Out	70.22M
EPS (ttm)	-10.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,655
Open	39.31
Previous Close	39.07
Day's Range	37.68 - 39.44
52-Week Range	33.36 - 85.53
Beta	0.94
Analysts	Buy
Price Target	93.39 (+147.13%)
Earnings Date	May 3, 2023

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysacc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,119
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE

Financial Performance

In 2022, RARE's revenue was $363.33 million, an increase of 3.39% compared to the previous year's $351.41 million. Losses were -$707.42 million, 55.8% more than in 2021.

Analyst Forecast

According to 25 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $93.39, which is an increase of 147.13% from the latest price.

Price Target

$93.39

(147.13% upside)

Analyst Consensus: Buy